ClinicalTrials.gg
RecruitingNCT06840678Updated Feb 21, 2025

Home-based Transcranial Static Magnetic Field Stimulation (tSMS) of the Supplementary Motor Area in Parkinson's Disease

A Phase 1 interventional study of Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area in Parkinson's Disease, sponsored by Fundación de investigación HM. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Fundación de investigación HM · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 225 studies in Parkinson Disease with a site in Spain — 37 open to participants now, 56 under way, 3 of them phase 3. Parkinson Disease · Spain.

Planned enrollment
159th of 179
20 · median 100
Started
2022
with 17 others
Phase 1
7 of 225
1 open now
Primary completion
2025-08
later than 14 of 55 live
Registered
171st of 225
by date

Among the 225 studies in Parkinson Disease with a site in Spain, this one is the 159th largest by planned enrollment of the 179 interventional ones that give a count, is one of 18 that started in 2022, is one of 7 in phase 1, reaches primary completion later than 14 of the 55 other live ones, and was the 171st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

37 of the 225 studies in Parkinson Disease with a site in Spain are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 225 studies in Parkinson Disease with a site in Spain, or all of them as a file.
02

Study summary

This is a pilot open study to test the hypothesis that home-based transcranial static magnetic field stimulation (tSMS) of the supplementary motor area is safe and feasible to modulate corticostriatal activity in patients with Parkinson's disease.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • idiopathic Parkinson's disease (Brain Bank criteria)
  • optimal clinical response to dopaminergic medication (>30% MDS-UPDRS-III improvement)

Exclusion criteria

Exclusion Criteria:

  • MRI-incompatible metal objects in the body (e.g. cardiac pacemakers)
  • presence of levodopa-induced dyskinesias
  • other main neuropsychiatric co-morbidity
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    tSMS

    30 min of tSMS, 5 daily sessions per week (monday to friday), for 8 weeks, at home

    Device: Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area

Interventions

  • DeviceTranscranial static magnetic field stimulation (tSMS) of the supplementary motor area

    Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. The investigators will use a cylindrical neodymium magnet of 60 mm diameter and 30 mm of thickness (MAG60r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the supplementary motor area (SMA) using an ergonomic helmet (MAGsv1.1, Neurek SL, Toledo, Spain).

    Also known as: MAGsv1.1 with MAG60r, Neurek SL, Toledo, Spain

06

What researchers measure

Primary outcomes

  1. Adverse events (safety)

    Number of device-related AE

    Time frame: From the start to 3 months after the end of treatment (5 months)

  2. Feasibility of home-based tSMS

    Number of home-based tSMS sessions completed, according to patient's diaries

    Time frame: From the start to the end of treatment (8 weeks)

Secondary outcomes

  1. Subjective improvement

    Patient global impression of change (PGIC)

    Time frame: Within one week after the end of treatment compared to baseline

  2. Motor improvement

    MDS-UDPRS III scale

    Time frame: Within one week after the end of treatment compared to baseline

  3. Sleep improvement

    SCOPA-sleep scale

    Time frame: Within one week after the end of treatment compared to baseline

Other outcomes

  1. Change in corticospinal excitability

    Amplitude of motor evoked potentials (MEPs) evoked by transcranial magnetic stimulation of the motor cortex

    Time frame: Within one week after the end of treatment compared to baseline

  2. Changes in corticostriatal activity by FDG-PET

    FDG-PET uptake in SMA and motor striatum

    Time frame: Within one week after the end of treatment compared to baseline

  3. Changes in corticostriatal activity by resting-state fMRI

    Functional connectivity between SMA and motor striatum

    Time frame: Within one week after the end of treatment compared to baseline

  4. Changes in corticostriatal microstructure by diffusion-tensor imaging (DTI)

    Fractional anisotropy and diffusivity in SMA and motor striatum.

    Time frame: Within one week after the end of treatment compared to baseline

07

Study locations

1 of 1 sites recruiting
  • HM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales
    Móstoles, Madrid 28938, Spain
    Recruiting
08

References and documents

Publications

  • Oliviero A, Mordillo-Mateos L, Arias P, Panyavin I, Foffani G, Aguilar J. Transcranial static magnetic field stimulation of the human motor cortex. J Physiol. 2011 Oct 15;589(Pt 20):4949-58. doi: 10.1113/jphysiol.2011.211953. Epub 2011 Aug 1. PubMed 21807616 ↗
  • Rivadulla C, Foffani G, Oliviero A. Magnetic field strength and reproducibility of neodymium magnets useful for transcranial static magnetic field stimulation of the human cortex. Neuromodulation. 2014 Jul;17(5):438-41; discussion 441-2. doi: 10.1111/ner.12125. Epub 2013 Oct 11. PubMed 24125470 ↗
  • Oliviero A, Carrasco-Lopez MC, Campolo M, Perez-Borrego YA, Soto-Leon V, Gonzalez-Rosa JJ, Higuero AM, Strange BA, Abad-Rodriguez J, Foffani G. Safety Study of Transcranial Static Magnetic Field Stimulation (tSMS) of the Human Cortex. Brain Stimul. 2015 May-Jun;8(3):481-5. doi: 10.1016/j.brs.2014.12.002. Epub 2014 Dec 11. PubMed 25595064 ↗
  • Dileone M, Carrasco-Lopez MC, Segundo-Rodriguez JC, Mordillo-Mateos L, Lopez-Ariztegui N, Alonso-Frech F, Catalan-Alonso MJ, Obeso JA, Oliviero A, Foffani G. Dopamine-dependent changes of cortical excitability induced by transcranial static magnetic field stimulation in Parkinson's disease. Sci Rep. 2017 Jun 28;7(1):4329. doi: 10.1038/s41598-017-04254-y. PubMed 28659614 ↗
  • Dileone M, Mordillo-Mateos L, Oliviero A, Foffani G. Long-lasting effects of transcranial static magnetic field stimulation on motor cortex excitability. Brain Stimul. 2018 Jul-Aug;11(4):676-688. doi: 10.1016/j.brs.2018.02.005. Epub 2018 Feb 7. PubMed 29500043 ↗
  • Pineda-Pardo JA, Obeso I, Guida P, Dileone M, Strange BA, Obeso JA, Oliviero A, Foffani G. Static magnetic field stimulation of the supplementary motor area modulates resting-state activity and motor behavior. Commun Biol. 2019 Oct 31;2:397. doi: 10.1038/s42003-019-0643-8. eCollection 2019. PubMed 31701026 ↗
  • Dileone M, Ammann C, Catanzaro V, Pagge C, Piredda R, Monje MHG, Navalpotro-Gomez I, Bergareche A, Rodriguez-Oroz MC, Vela-Desojo L, Alonso-Frech F, Catalan MJ, Molina JA, Lopez-Ariztegu N, Oliviero A, Obeso JA, Foffani G. Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson's disease: A randomized controlled trial. Brain Stimul. 2022 May-Jun;15(3):857-860. doi: 10.1016/j.brs.2022.05.012. Epub 2022 May 21. No abstract available. PubMed 35609815 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Aug 2025, 34 months after the start.

Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 34 months is close to that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Feb 21, 2025
StartActual
Oct 1, 2022
Primary completionEst.
Aug 31, 2025
CompletionEst.
Aug 31, 2025
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06840678
Lead sponsor
Fundación de investigación HM
Responsible party
Guglielmo Foffani (PhD, Fundación de investigación HM) — Principal investigator
First posted
Feb 21, 2025
Start date
Oct 1, 2022
Primary completion
Aug 31, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Feb 21, 2025

Study contacts

Guglielmo Foffani, PhD
Contact
gfoffani.hmcinac@hmhospitales.com
+34 - 91 26 73 201
Guglielmo Foffani, PhD
principal investigator · HM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales, Móstoles, Madrid, Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion